Previous 10 | Next 10 |
Mesoblast ( NASDAQ: MESO ) reports net cash usage for operating activities in the Q3 of $14.3M; representing a reduction of $3.9M, or 22%, on the comparative quarter in FY2022, and a reduction of $8M, or 47%, on the comparative quarter in FY2021. Cash on hand was $85....
NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended September 30, 2022. Financial Highlights Net cash us...
Summary Due to an extended downtrend in Athersys stock price due largely to a declining cash position, Athersys currently trades at a market cap near $24 million. The current valuation is miniscule when compared to valuations of other stem cell companies, especially when consideri...
NEW YORK, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that it has submitted to the U.S. Food and Drug Administration (FDA) substantial new information on clinical and po...
Mesoblast press release ( NASDAQ: MESO ): FY GAAP EPS of -$0.14. Revenue of $10.21M (+36.9% Y/Y). BLA resubmission to FDA expected by the end of Q3 CY2022. As of June 30, 2022, cash was $60.4M, with pro-forma $105.5M after raising gross proceeds of $45M via a priva...
Mesoblast Limited (MESO) Q4 2022 Earnings Conference Call August 30, 2022, 06:30 PM ET Company Participants Silviu Itescu - CEO and MD Andrew Chaponnel - Interim CFO Eric Rose - Chief Medical Officer Conference Call Participants Michael Okunewitch - M...
The following slide deck was published by Mesoblast Limited in conjunction with their 2022 Q4 earnings call. For further details see: Mesoblast Limited 2022 Q4 - Results - Earnings Call Presentation
At June 30, 2022, cash-on-hand was US$60.4 million with pro-forma US$105.5 million after raising gross proceeds of US$45 million via a private placement in August, 2022 Up to an additional US$40 million available from existing facilities subject to certain milestones Net...
NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Jane Bell to its Board of Directors. Ms Bell is a banking and finance lawyer with 22 years of...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock We’re starting off the day with a breakdown of the biggest pre-market stock movers investors will want to watch on Tuesday! Moving stocks this morning is a guidance update, public offerin...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...